- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02244294
FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)
A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Phase I
- Adult men, 45 years of age or older, diagnosed with acute urinary retention due to BPH
- Patients who have never taken alpha-blockers or discontinued taking alpha-blockers 72 hours or more prior to entrance into this study
- Patients that have been treated with an indwelling urethral catheter as treatment for acute urinary retention (AUR) due to BPH
- Patients must be judged by the investigator to be reliable and willing to comply with all tests and examinations stipulated in the protocol
- All patients must be willing to give meaningful, written, informed consent prior to participation in the trial, in accordance with regulatory requirements. Patients must also have sufficient understanding to communicate effectively with the investigator
Phase II - Patients who voided spontaneously, at least 100 mL and a post-void residual volume of ≤ 300 mL, at Visit 2
Exclusion Criteria:
Phase I
Patients diagnosed with a symptomatic/active urinary tract infection (UTI) or an abnormal urine culture at baseline or 2 or more UTIs within the last six months. An abnormal urine culture was defined as:
- A bacterial colony count of greater than or equal to 100,000 CFU/mL or
- A bacterial colony count of greater than or equal to 100 CFU/mL of a known urinary pathogen in a symptomatic patient
- Patients that have a distended bladder volume greater than 1.5 liters (1500 ml) of retention as measured by initial catheter urine volume
- Patients with history of sexually transmitted disease within last two years
- Patients with active genital herpes disease whose urinary function was impacted due to the disease
- Patients who have a history of mechanical outlet obstruction excluding BPH (i.e., bladder neck contracture or stricture, bladder tumor, or bladder calculi)
- Patients with urethral stricture disease
- Patients with a history of bladder, prostate, or urethral surgery in the last three months
- Patients presenting with AUR who were not been seen within 5 days of urethral catheter placement
- Patients presenting with any of the following: active urinary stone disease, previous pelvic radiotherapy, perirectal inflammatory disorders or inflammatory bowel disease
- Participation in another drug study within 30 days of Visit 1
- Clinically relevant conditions which may interfere with the patient's ability to participate in the study including, but not limited to, the following: neurologic, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, hematologic or respiratory disease and clinically relevant laboratory abnormalities not mentioned above (e.g., hematuria) based upon the clinical judgment of the investigator
- Patients receiving cimetidine, ranitidine or warfarin within two weeks of study start date and who would potentially use such medications during the course of the trial
- Patients currently treated with finasteride (PROSCAR®) and who would not discontinue its use upon entrance into the study
- Patients with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other alpha-blockers
- Patients with a history of myocardial infarction within six months of baseline
- Patients with uncontrolled hypertension (systolic > 160 mmHg, diastolic > 100 mmHg) and patients with severe hypotension (systolic < 90 mmHg)
Patients who have been using the following drugs, 72 hours prior to study start date, or who are unable to discontinue these drugs over the course of the study:
- Alpha-adrenergic medication
- Drugs with systemic anticholinergic activity including antihistamines. The following antihistamines are allowed: ALLEGRA®, CLARITIN® or ZYRTEX®
- Antispasmodics or muscle relaxants
- Parasympathomimetics, cholinomimetics or similar drug
- Patients that have poorly controlled diabetes mellitus who suffer from peripheral neuropathy or diabetic cystopathy
- Patients who suffer from neurological diseases affecting the bladder (i.e., multiple sclerosis, Parkinson's disease, stroke, and any bladder trauma that may be an exclusion criterion in the opinion of the investigator
- Patients with a neurological impairment or psychiatric disorder that prevents their comprehension of the informed consent and/or the ability to comply with the protocol
- Patients with a urine volume at the initial catheterization less than 300 mL
- Patients with a diagnosis of active cancer, except basal cell carcinoma, within 5 years or less
- Patients who had a transurethral resection of the prostate (TURP) within 5 years or less of study enrollment and irreversible urethral damage due to the procedure
Phase II
- Patients with clinically, significant abnormal lab results including any baseline laboratory serum test with the following values:
- Hemoglobin < 11.0 g/dL
- Leukocytes < 3,000 per mm3
- Liver enzymes [aspartate aminotransferase (SGOT), alanine transaminase (SGPT) and alkaline phosphatase]: more than two times the upper limit of normal at baseline
- Serum creatinine more than two times the upper limit of normal at Visit 1
- Patients with clot retention, persistent gross hematuria (Visit 3 only), prostatitis, a symptomatic/active urinary tract infection (UTI) or an abnormal baseline urine culture
- An abnormal urine culture was defined as:
- A bacterial colony count of greater than or equal to 100,000 colony forming units (CFU)/mL or
- A bacterial colony count of greater than or equal to 100 CFU/mL of a kown urinary pathogen in a symptomatic patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: FLOMAX®
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Successful spontaneous voiding after urethral catheter removal
Time Frame: Up to 96 hours after start of treatment
|
For Phase I of the trial
|
Up to 96 hours after start of treatment
|
Maintenance of successful spontaneous voiding
Time Frame: Up to 6 months after start of treatment
|
For Phase II of the trial
|
Up to 6 months after start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events
Time Frame: Up to 6 months
|
Up to 6 months
|
|
Change in voided urine volume
Time Frame: Up to 6 months after start of treatment
|
Up to 6 months after start of treatment
|
|
Determination of post-void residual urine volume
Time Frame: Up to 6 months after start of treatment
|
by ultrasound or bladder scan
|
Up to 6 months after start of treatment
|
Time to recurrence of AUR
Time Frame: Up to 6 months after start of treatment
|
For phase II of the trial
|
Up to 6 months after start of treatment
|
Clinically significant changes from baseline in vital signs
Time Frame: Pre-dose, up to 6 months after start of treatment
|
Pre-dose, up to 6 months after start of treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Prostatic Diseases
- Urination Disorders
- Prostatic Hyperplasia
- Hyperplasia
- Urinary Retention
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Tamsulosin
Other Study ID Numbers
- 527.26
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Hyperplasia
-
Yonsei UniversityCompletedBPH( Benign Prostate Hyperplasia) | TURP(Transurethral Resection of Prostate)Korea, Republic of
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Uppsala UniversityHelsingborgs Hospital; Sormland County Council, Sweden; Centrallasarettet Västerås and other collaboratorsRecruitingProstate Hyperplasia | Embolization, Therapeutic | Transurethral Resection of Prostate SyndromeSweden
-
St. Luke's Medical Center, PhilippinesCompletedBenign Prostatic Hyperplasia | Prostate Cancer | ProstatitisPhilippines
-
Ziv HospitalNot yet recruitingInflammation | Prostate Neoplasm | Benign Hyperplasia of Prostate
-
GCS Ramsay Santé pour l'Enseignement et la RechercheNot yet recruiting
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Clinique Saint-HilaireCompletedProstate HyperplasiaFrance
-
Adana City Training and Research HospitalCompleted
-
Kafrelsheikh UniversityCompleted
Clinical Trials on FLOMAX® capsules
-
Boehringer IngelheimCompleted
-
Azienda Ospedaliera Universitaria Policlinico "G...Completed
-
Sun Yat-sen UniversityCompleted
-
Boehringer IngelheimCompleted
-
Genzyme, a Sanofi CompanyCompletedSecondary HyperparathyroidismUnited States
-
Shandong UniversityQilu Hospital of Shandong UniversityRecruitingHigh Risk Human Papillomavirus Infection | Low Grade Squamous Intraepithelial LesionChina
-
BioseCompleted
-
GenMont Biotech IncorporationBiomedical Development CorporationCompletedProbiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)Taiwan
-
Burnasyan Federal Medical Biophysical CenterCompletedAngina Pectoris | Stroke, Not Specified as Hemorrhage or InfarctionRussian Federation
-
Al-Mustafa University CollegeRecruitingDiabetes Mellitus, Type 2Iraq